1 Predictors of mortality among COVID-19 patients at Kilimanjaro Christian

2 Medical Centre in Northern Tanzania: A hospital-based retrospective cohort

- 3 *study*
- 4 Gilbert G. Waria^{1*}, Florida J. Muro^{1,2,3¶}, Norman Jonas^{3,4&}, Francis Sakita^{6&}, Laura
- 5 Shirima¹, Henry L. Mlay^{1&}, Michael Ngowi^{1&}, Elvis B. Meela^{1&}, Innocent B. Mboya^{1,2,5}
- 6 Kajiru G. Kilonzo^{3,4&}

7 Affiliations

- 8 ¹Department of Epidemiology and Biostatistics, Institute of Public Health, Kilimanjaro
- 9 Christian Medical University College, Moshi Tanzania
- 10 ²Department of Community Medicine, Institute of Public Health, Kilimanjaro
- 11 Christian Medical University College, Moshi, Tanzania
- 12 ³Kilimanjaro Christian Medical Centre, Moshi, Tanzania
- ⁴Department of Internal Medicine, Kilimanjaro Christian Medical University College, Moshi,
- 14 Tanzania
- 15 ⁵Department of Translational Medicine, Lund University, Malmö, Sweden,
- 16 ⁶Emergency Medicine Department, Kilimanjaro Christian Medical Centre, Moshi, Tanzania
- 17
- 18 *Corresponding author: Gilbert G. Waria
- 19 E-mail: <u>waria751@gmail.com</u> (GGW)
- 20 These authors contributed equally to this work.
- 21 & These authors also contributed equally to this work.

22 Author emails:

- 23 GGW: <u>waria751@gmail.com</u>
- 24 FJM: <u>floridajm@yahoo.com</u>
- 25 NJ: norman.jonas@kcmuco.ac.tz
- 26 FS: francis.sakita@gmail.com
- 27 LS: <u>shirimalaura@gmail.com</u>
- 28 HLM: <u>henrymlay54@gmail.com</u>
- 29 MN: michaelngowi123@gmail.com
- 30 EBM: <u>elvismeela@yahoo.com</u>
- 31 IBM: innocent.mboya@med.lu.se
- 32 KOK This preprint reports new gesearch that has not been certified by peer review and should not be used to guide clinical practice.

33 Abstract

Background: COVID-19 disease is a global public health disaster causing a range of social, economic, and healthcare difficulties, border restrictions, high human loss, lockdown, and transportation challenges. Despite it being a global pandemic, there are few studies conducted in Tanzania to examine the predictors of mortality. This disease has caused a significant number of mortalities worldwide but literature shows low mortality and better survival in Africa than in other WHO regions. Therefore, this study aimed to determine the predictors of mortality among COVID-19 patients at KCMC Hospital in Northern Tanzania.

41 Methodology: This was the hospital-based retrospective cohort study, conducted at 42 KCMC Hospital in Northern Tanzania among all admitted patients with confirmed COVID-43 19, from 10th March 2020 to 26th January 2022. The main study event was COVID-19 44 mortality. The predictors of mortality were determined by using the Weibull survival regression 45 model and the statistically significant results were declared at a p-value of <0.05.</p>

46 **Results:** A total of 547 confirmed COVID-19 patient records were included in the study. Their median age was 63 (IQR; 53-83), about 60% were aged 60 years and above, and 56.7% 47 48 were males. The most common clinical features were; fever (60.8%), a severe form of the disease (44.4%), difficulty in breathing (73.3%), chest pain (46.1%), and generalized body 49 weakness (71.3%). Of all participants, over one-third (34.6%) died (95%CI; 0.31-0.39). The 50 median survival time was 7 days (IQR; 3-12). The overall mortality rate was 32.33 per 1000 51 person-days while the independent predictors of higher mortality risk were age ≥ 60 years 52 (AHR=2.01; 95%CI 1.41-2.87; P<0.001), disease severity (AHR=4.44; 95%CI 2.56-7.73; 53 P<0.001) and male sex (AHR=1.28; 95%CI; 0.93-1.73; P=0.128). 54

55 **Conclusion:** Mortality was higher in elderly male patients, with a severe form of the 56 disease and those with any comorbidities. Therefore, more attention should be provided to older 57 patients including uptake of the current vaccine and ensuring standard and supportive care at 58 primary health facilities is available.

59 **Keywords**: Mortality rate, Mortality, Predictors, COVID-19, Tanzania.

60 Introduction

On 31 December 2019, the World Health Organization (WHO) was informed of a cluster of cases of pneumonia of unknown cause detected in Wuhan, Hubei Province, China. This condition is due to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), causing a range of clinical signs including fever, cough, asthenia, or respiratory distress. The virus has spread rapidly worldwide since its outbreak with the WHO declaring it a pandemic [1] As of July 8, 2022, more than 500 million cases of COVID-19 have been reported across the world, resulting in more than 6 million deaths[2].

The global COVID-19 data showed America, Asia, and Europe to be the most hit continents with COVID-19 with poor survival rates among cases as compared with other continents like Africa which had better survival [1]. The first confirmed case of COVID-19 in Africa was reported in Egypt on February 14, 2020, and on April 19, 2020, Egypt has reported 3144 cases of COVID-19 and 239 deaths. The case fatality rate of COVID-19 varies across countries with an average of 4.2 ± 3.8 , among the older population [4, 5]

In China, Most of the mortality cases were reported among men, and less than half had 74 underlying diseases including diabetes, hypertension, and cardiovascular disease [6, 7]. There 75 is a better survival rate for COVID-19 patients, who are not living with comorbidities, such as 76 77 hypertension, diabetes. liver disease. renal disease. neurological disease. and immunocompromised [8]. 78

In 2020, South Africa, Egypt, Morocco, Nigeria, and Ghana were the African countries with the highest number of cases of COVID-19 [9]. Mortality was higher among older individuals (60+ years), with chronic disease and travel history, but with a lower mortality rate of 5.6% compared to European countries [10]. Nevertheless, Africa has been threatened by insufficient infrastructure and weak healthcare systems, putting the social-economic status of Africa under

control [11]. Some highlights in Africa that have been mentioned as predictors of low mortality
include high temperature, humidity, early use of BCG vaccination, and possibly a different
viral subtype [12].

In Tanzania, the first case of COVID-19 was imported on 16th March 2020 and declared by the Ministry of Health, Community Development, Gender, Elderly, and Children [MoHCDGEC] on 14th April 2020 that there was a community transmission, with more than five hundred (509) confirmed cases and 21 deaths related to COVID 19 [13]. Currently, we have more than 35,000 confirmed cases and more than 800 deaths as of July 8, 2022 [14]

Interventions to improve survival among COVID-19 cases include ongoing vaccination, 92 Infection Prevention and Control (IPC) policy through the use of personal protective 93 equipment/gear, continuous education, community engagement, and protection of high-risk 94 95 groups including healthcare workers, older adults, and those with underlying conditions or comorbidities [14-18]. However, the number of new infections and deaths attributed to 96 COVID-19 continues to spike in various communities and regions. In 2021, Kilimanjaro and 97 Mwanza regions which are surrounded by Kenya and Uganda in the Northern and 98 Northwestern part of Tanzania were the most regions affected by the disease [14]Currently, 99 more than 3 Million people have received at least one COVID-19 vaccine dose in Tanzania 100 [19]. Despite that, Tanzania lacks studies documenting COVID-19-related mortality and 101 associated predictors. Therefore, this study aimed to determine predictors of mortality among 102 COVID-19 patients admitted at a zonal referral hospital in Northern Tanzania. 103

104 Methods

105 Study design, setting, and population

106 This was a hospital-based retrospective cohort study, which involved the analysis of all COVID-19 patients admitted at the KCMC hospital from 10th March 2020 to 26th January 2022 107 comprising data from all four COVID-19 waves in Tanzania. We used data available in Excel 108 format of the electronic isolation database. The data contained the patient's information on 109 socio-demographic characteristics, clinical features, and comorbidities. The electronic patient 110 records were collected and filled in by the clinicians at clinical examinations. A total of 1117 111 COVID-19 patient records were retrieved from the electronic files, only 570 Confirmed 112 COVID-19 were enrolled. The study excluded patients with incomplete information such as 113 the unknown discharge status, and dates of admission and discharge (n=23), which was crucial 114 for our statistical analyses and after removing duplicate patient records only 547 confirmed 115 COVID-19 cases were available for analysis (S1 Fig). 116

117 Variables

The main event of interest was COVID-19 mortality which was defined based on the certified cause of death due to COVID-19 documented in the patient's electronic files. The earliest observed date was 10th March 2020 while the latest exist date was 26th Jan 2022.

Independent variables included patients' socio-demographic characteristics, clinical features at 121 admission, and comorbidities. The study's selection and categorization of independent variables 122 were based on previous literature [16]. Patients' socio-demographic characteristics included age 123 in years (<60, ≥ 60 years), sex (male, female), and residence region (Arusha, Kilimanjaro, others). 124 Clinical features at admission were measured based on the defined WHO cutoff points; Disease 125 126 severity, Mild case if Oxygen saturation \geq 94% on RA+ No clinical or radiological evidence of pneumonia, Moderate case if oxygen saturation 90-94% on RA+ clinical or radiological evidence 127 of non-severe pneumonia ,Severe case if oxygen saturation 80-89% on RA+ clinical or 128

radiological evidence of severe pneumonia . COVID-19 symptoms, specifically fever, headache,
nausea, cough, difficulty in breathing, chest pain, generalized body weakness, sore throat, runny
nose, smell loss, loss of taste, abdominal pain, and diarrhea were recorded and measured based
on patient/relative report and clinician assessment ("Yes" if had any symptom and "No" if had
no symptoms).

Furthermore, the comorbidities were the presence of hypertension, diabetes, liver disease, asthma, renal disease, neurological disease, immunodeficiency, and malignancy. Patients were also considered to have comorbidities if they had a history of comorbidities or taking any anticomorbidities drugs such as antihypertensive, antidiabetic, antiviral, anticancer drugs, and being under current care/management receiving (Yes/No). Abnormal chest x-ray and abnormal lung auscultation were defined based on the radiological finding.

140 Data analysis

We performed all statistical analyses using Stata version 15 (Stata Corp. 2017). Stata statistical 141 software: Release 15. College Station, TX: StataCorp LLC). We summarized numerical 142 variables (age and Oxygen saturation at admission) using median (interquartile range) and 143 categorical variables using frequencies and percentages. The Chi-square test was used to test 144 the association between mortality and socio-demographic characteristics, clinical features, and 145 comorbidities at a 5% threshold level. We compared patient survival experiences using the 146 147 Kaplan-Meier survival function and Nelson-Aalen cumulative hazard plots with the Log-rank test. The mortality rate was estimated using the Poisson survival regression model while the 148 Weibull regression model was used to estimate the associated predictors [21]. Model 149 150 comparison was done using the Akaike Information Criteria (AIC), the lowest value indicating the best-fitting model. 151

152 Crude/unadjusted Weibull regression determined the association between mortality and 153 participant characteristics. The crude hazard ratio (CHR) and corresponding 95% confidence 154 intervals (CI) were reported for variables of clinical importance such as hypertension, diabetes, 155 age, and sex. We further developed a multivariable Weibull regression model to determine 156 mortality predictors adjusted for potential confounders. The model estimated the adjusted 157 hazard ratio (AHR) and the corresponding 95% CI.

158 Ethical consideration

Permission to use the COVID-19 data with reference No.KCMC/P.I/Vol.IX was granted by the KCMC Hospital executive director's office. Unique patient identification instead of hospital numbers was used to maintain confidentiality. Ethical approval to carry out the current study was obtained from the Kilimanjaro Christian Medical College Research Ethics and Review Committee (KCMU-CREC) with clearance number PG 15/2021.

164 **Results**

165 Characteristics of the studied COVID-19 patients

Among 547 patients who tested positive for COVID-19 and met inclusion criteria, 324 (60%) 166 were aged 60 years and above with a median age of 63 (IQR: 50-75), and more than half of 167 them were males 310 (56.7%) (S1 Table). Most of the study participants presented with fever 168 333 (60.8%), a severe form of COVID-19 243 (44.4%), difficulty in breathing 424 (73.3%), 169 chest pain 252 (46.1%), and generalized body weakness 390 (71.3%). Two-thirds of the 170 participants 375 (68.6%) were exposed during waves 2 & 3; their median oxygen saturation at 171 the time of attending the hospital was 70% (IOR: 53-82) (S2 Table). Abnormal chest x-ray 458 172 (83.7%), abnormal lung auscultation 274 (50.1%), hypertension 255 (46.6%), and diabetes 159 173 (29.1%) were the most common comorbidities (S3 Table). 174

175 Proportions of COVID-19 deaths by participant characteristics

- 176 Of 547 COVID-19 patients, 189 (34.6%) died and 358 (65.5%) were discharged alive. The
- median survival time was 7 days (IQR:3-12 days). The overall mortality rate was 32.33,
- 178 95%CI; 27.8-37.3 per 1000 person-days. Mortality occurred in 141 (43.5%) of the elderly
- 179 patients (P<0.001) and 113 (36.5%) in male patients (P=0.285) (S2 and S3 Table). The
- proportion of deaths was higher in 140 (57.6%) patients with a severe form of the disease
- 181 (p<0.001), among 154 (38.4%) patients who present with difficulty in breathing (p=0.002), 133
- 182 (35.5%), 31 (43.7%) in patients exposed during waves 2&3 and 4, respectively (p=0.03), 19
- 183 (25.7%) who reported to loss of taste (p-value =0.084) and in 10 (22.7%) among those who
- reported having had diarrhea episodes (p-value=0.085) (S2 Table).
- Among individuals with comorbidities, 66 (41.5%) patients with diabetes (p=0.028), 172
- 186 (37.6%) with abnormal chest x-ray (p < 0.001), 110 (40.2%) with abnormal lung auscultation

187 (p=0.006), and 13 (54.2%) = with renal disease (p=0.003) had died (S3 table).

188 Mortality rate experience of COVID-19 patients

The overall mortality rate was 32.33, 95%CI; 27.8-37.3 per 1000 person-days. The mortality 189 rate (MR) per 1000 person-days was 46.7 (95%CI; 39.4-55.4) in patients over 60 and 190 (MR=37.1, 95%CI; 30.8-44.5) in male patients. Furthermore, patients with moderate and 191 severe forms of the disease had mortality rates of (MR=19.2, 95%CI; 13.3-27.4) and 192 193 (MR=55.0, 95%CI; 46.4-65.2), respectively. The mortality rate (per 1000 person-days) among patients presenting with breathing difficulties was (MR=35.4, 95%CI; 30.1-41.6), and in 194 diabetic patients was (MR=39.4, 95%CI; 30.7-50.6). In addition, the mortality rate was 195 (MR=36.9, 95%CI; 30.0-45.2) in hypertensive patients, (MR=34.5, 95%CI; 29.6-40.2) among 196 patients with abnormal chest x-rays, and (MR=37.8, 95%CI; 31.2-45.9) among those with lung 197 auscultations. Patients with renal disease had a mortality rate of (MR=37.8, 95%CI; 31.2-45.9) 198 per 1000 person-days (S2 Fig). 199

200 **Predictors of COVID-19 mortality**

223

The predictors associated with COVID-19 mortality are displayed in (Tables S4, S5 & S6). In 201 crude analysis Age, Sex, Disease severity, Difficult in breathing, Abnormal chest X-ray, 202 Abnormal Lung auscultation and renal diseases were the significant predictor, the hazard of 203 mortality among patients aged >60 years was 2.62 times significant higher, compared to those 204 aged <60 years (CHR=2.62; 95%CI 1.88-3.66; P <0.001). Males had 1.35 times significant 205 higher the hazard of mortality compared to females (CHR=1.35; 95%CI 1.00-1.83; P= 0.049). 206 Compared to the mild form of the disease, patients with moderate form had a 1.91 times higher 207 208 hazard of mortality (CHR=1.91; 95%CI 1.03-3.53; P <0.041). Compared to the mild form of the disease, patients with the severe form had a 5.54 times higher hazard of mortality 209 (CHR=5.54; 95%CI 3.25-9.44; P <0.001). Patients who present with Difficult breathing had 210 211 1.56 times the significant higher hazard of mortality compared to those without (CHR=1.56; 95%CI 1.06-2.28; P=0.023), compared to patients living without diabetes, diabetes patients 212 had 1.33 times the significant higher hazard of mortality (CHR=1.33; 95%CI 0.98-1.82; P= 213 0.066). Patients found with abnormal chest X-rays had 1.75 times the significant higher hazard 214 of mortality compared to patients without abnormal chest x-ray, (CHR=1.75; 95%CI 1.06-215 2.88; P=0.028). Patients with abnormal lung auscultation had 1.41 times the significant higher 216 hazard of mortality compared to a patient with normal lung auscultations (CHR=1.41; 95%CI 217 1.05-1.89; P = 0.024). Lastly, compared to patients without renal disease, patients with renal 218 219 disease had a 1.89 times higher hazard of mortality (CHR=1.89; 95%CI 1.08-3.33; P= 0.027). In the adjusted analysis, the significantly higher mortality risk was among the elderly aged ≥ 60 220 years (AHR=2.01; 95%CI 1.41-2.87; P<0.001), male patients (AHR=1.27; 95%CI 0.93-1.73; 221 222 P=0.128), patients diagnosed with moderate (AHR=1.67; 95%CI 0.89-3.13; P=0.112) and severe form of COVID-19 (AHR=4.44; 95%CI 2.56-7.73; P<0.001), those exposed during

wave 2 & 3 (AHR=1.58; 95%CI 1.03-2.41; P=0.036), and in diabetes patients (AHR=1.25;
95%CI 0.88-1.79; P=0.212) (S7 Table).

226 **Discussion**

This study aimed to determine the predictors of mortality among COVID-19 patients at KCMC 227 referral Hospital in northern Tanzania. The overall proportion of death due to COVID-19 228 among the studied patients was 34.6%, which is consistent with findings in Italy at 37.6% [3], 229 Democratic republic of Congo at 32% [16], and in Dar es Salaam Tanzania at 31.8% [18]. 230 Much lower prevalence was reported in India (14.4%) [19] and Tanzania (14.9%) [20], due to 231 severe form of disease,, pre-existing comorbidities, and advanced age. The overall mortality 232 rate in this study was 32.3 per 1000 person-days, which is lower than those reported in other 233 settings [25-29]. Possible explanation may be the healthcare setting infrastuctures, Manpower 234 and its accessibility, geographical location, or personal behaviors. 235

236 The median survival time was 7days (IQR:3-12] Similar to findings in East India 8days (IQR:7-

237 10) [30], Ethiopia 9days (IQR:8-12), [26] USA 5days(IQR:3-10) [25], Tanzania 3days(IQR:1-

6] [24], 12days Congo [16],Different findings in Ethiopia 44days(IQR:28-74) [29] Probable
reasons living environment, Setting in which the patient receive care and attitudes toward
COVID-19.

Older patients had a higher mortality risk compared to patients less than 60 years. The finding is similar to studies conducted in Northern Italy [5], Brazil [25], the Democratic Republic of Congo [16], and Tanzania [18]. This observation amongst the elderly may be due to immunodeficiency, and comorbidities, as it increases with age, which results in higher morbidity and mortality [26].

Mortality among males with COVID-19 was higher compared to females, which is similar to studies conducted elsewhere [20, 24, 32, 34-38]. The reasons for higher risk in males compared

to females could be due to sex-specific hormones, and immune responses. Higher expression
of Angiotensin-converting enzymes, Risk-taking behaviors and lifestyle, comorbidities,
irresponsible attitudes toward the COVID-19 pandemic frequent hand washing, wearing masks
and homestay, and hormonal difference [37, 38].

COVID-19 mortality was significantly higher among patients with moderate (18.3%) and severe forms of the disease (57.6%) compared to those with mild forms (13.2%). Patients with moderate and severe forms of the disease are consistently reported to have a higher mortality risk [23, 34, 39-42]. Weak immune functions, elderly age, limited organ compensatory function, more basic disease before infections, poor history of healthcare-seeking behaviors in the African setting, higher neutrophils count, lower lymphocytes, and platelet count could explain the observed findings [23, 39, 40].

Being exposed during waves 2 & 3 was a significant predictor of mortality. The wave exposure happened at different times across the world. Therefore the findings of these waves are not consistent at all compared to other settings as they occurred at different times and settings. Low mortality was observed among patients exposed to waves 1 and 4 respectively.

Different studies reported a higher mortality risk among elderly patients with one or more than two pre-existing comorbidities, especially hypertension, diabetes, and renal disease [22, 24, 31, 34, 43, 44], which was similar to the findings in this study. These studies found diabetes and hypertension as important risk factors for COVID-19 severity and mortality. The observed difference may be due to lifestyle, eating habits, sedentary lifestyle and low prevalence of Non-Communicable diseases in sub-Saharan Africa.

270 Strengths

This study is the first to determine the predictors of mortality among COVID-19 confirmed cases at KCMC zonal referral hospital in Northern Tanzania. Secondly, the survival analysis which take into account variable time was carried out which make this study unique compared to others done in Tanzania. Thirdly, Data analysis and experience set a baseline for further studies in addressing the area of improvement within our country.

276 Limitations

We were unable to obtain all important data related to the outcome of interest as the use of 277 secondary data limit the prediction of the existing data and patient monitoring. Secondly, this 278 study is single centered thus these results cannot be generalized to all COVID-19 patients 279 admitted in the other settings. Thirdly, the external validation was limited as the studied number 280 of patients were not sufficient enough to identify both potential predictors associated with the 281 outcome. Fourthly, being historical cohort study, retrieving complete information was 282 difficulty lack of some information's might underestimate or overestimate the outcome. Lastly, 283 Patients in this study were only studied up to their date of discharge, it would be of more interest 284 and benefit if they were studied beyond this time. Furthermore, it also includes the usual 285 286 limitations of retrospective studies.

287

288 **Conclusion**

Mortality was higher in elderly male patients, with a severe form of COVID-19, who were exposed during waves 2 & 3, and those with any comorbidities. Therefore, more attention should be provided to older patients, and ensuring standard and supportive care at primary health facilities are available.

293 **Recommendations**

Ensure that standard and supportive care are also available at the primary health facilities to allow early intervention to take place among patients diagnosed with the severe form of the disease because some patients were transferred late to referral hospitals which turnout in poor clinical outcome.

A further large multicenter quantitative study should be carried out by using both signs, symptoms, pre-existing comorbidities, laboratory parameters, and radiological and pathological findings to identify the potential predictors of mortality among COVID-19 patients, to allow external validation. Furthermore, a clinical trial study is needed to explore the sex differences in susceptibility, severity and outcomes of coronavirus diseases in 2019.

303 Abbreviations

304	COVID-19	Coronavirus disease of 2019
305	DIB	Difficulty in breathing
306	DM	Diabetes mellitus
307	GBW	Generalized Body weakness
308	HIV	Human Immunodeficiency Virus
309	IPC	Infection Prevention and Control
310	KCMC	Kilimanjaro Christian Medical Centre
311	KCMUCo	Kilimanjaro Christian Medical University College
312	МоН	Ministry of Health
313	PCR	Polymerase Chain Reaction
314	SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus-2

315 WHO

World Health Organization.

- 316 Consent for publication
- 317 Not applicable
- 318 Availability of data and materials
- 319 Data will be made available
- 320 Competing Interest
- 321 None of the authors has any conflict of interest in the content of this manuscript.

322 Acknowledgment

- 323 We acknowledge all doctors at KCMC who took part in data collection and all patients whose
- 324 information enabled the availability of data used in this study. The authors also thank the
- 325 KCMC isolation team for capturing these data in the electronic system.

326 Author's contributions

- GGW, FJM, IBM, KGK and NJ contributed to the design of the study. GGW performed the
- 328 statistical analysis and drafted the manuscript. LS, HLM, EBM and MN participated in
- 329 statistical analysis and drafting of the manuscript. FJM, IBM, KGK and FS edited the final
- draft of the manuscript and approved the final manuscript.

331 **REFERENCES**

1. WHO (2020) Coronavirus Disease (COVID-19) Situation Reports U	pdates 27
--	-----------

- 333 September 2020. World Health Organ Tech Rep Ser 1–23
- 2. WHO (2022) COVID-19 Weekly Epidemiological Update. World Heal Organ 1–23
- 335 3. Spiteri G, Fielding J, Diercke M, et al (2020) First cases of coronavirus disease 2019 (
- 336 COVID-19) in the WHO European Region , 24 January to 21 February 2020. 2019:
- 4. Alshogran OY, Altawalbeh SM, Al-azzam SI, Karasneh R (2021) Predictors of Covid-

33819 case fatality rate : An ecological study. Ann Med Surg 65:102319

- 5. Ferroni E, Rossi PG, Alegiani SS, et al (2020) Survival of hospitalized COVID-19
- patients in Northern Italy: A population-based cohort study by the ITA-COVID-19

341 network. Int J Environ Res Public Health 17:1–12

- Lei J, Li M, Wang X (2021) Predicting the development trend of the second wave of
 COVID-19 in five European countries. J Med Virol 93:5896–5907
- 344 7. Wang Y, Hospital CF, Ren L, Fan G, Hospital CF, Gu X, Hospital CF (2020) Articles
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
 https://doi.org/10.1016/S0140-6736(20)30183-5
- Emami A, Javanmardi F, Akbari A, Kojuri J, Bakhtiari H, Rezaei T, Keshavarzi A,
 Falahati F (2021) Survival rate in hypertensive patients with. Clin Exp Hypertens
 43:77–80
- 3509.Lot M, Hamblin MR, Rezaei N (2020) Since January 2020 Elsevier has created a
- 351 COVID-19 resource centre with free information in English and Mandarin on the
- novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier
- 353 Connect, the company's public news and information.

	354	10.	Mohammed M.	Muhammad S.	Mohammed FZ.	Mustapha S.	Sha A	, Sani NY.	Ahmad
--	-----	-----	-------------	-------------	--------------	-------------	-------	------------	-------

- 355 MH, Bala AA (2020) Risk Factors Associated with Mortality Among Patients with
- 356 Novel Coronavirus Disease (COVID-19) in Africa. 6–11
- 11. Rosenthal PJ, Breman JG, Djimde AA, John CC, Kamya MR, Leke RGF, Moeti MR,
- 358 Nkengasong J, Bausch DG (2020) Editorial COVID-19 : Shining the Light on Africa.
 359 102:1145–1148
- Medhat MA, Kassas M El (2020) COVID-19 in Egypt : Uncovered figures or a
 different situation ? 10:2–5
- 362 13. Sarvas J (1987) Basic mathematical and electromagnetic concepts of the biomagnetic
 363 inverse problem. Phys Med Biol 32:11–22
- MoHCDGEC (2021) THE UNITED REPUBLIC OF TANZANIA Weekly trend of
 COVID-19 Confirmed Cases. 1–7
- 36615.Goyal ADK, Mansab AF, C BAI, D SB (2020) Early intervention likely improves
- 367 mortality in COVID-19 infection. 248–250
- 16. Nlandu Y, Mafuta D, Sakaji J, et al (2021) Predictors of mortality in COVID 19
- patients at Kinshasa Medical Center and a survival analysis : a retrospective cohort
 study. BMC Infect Dis 1–11
- 17. Methods C, Vienna LS, Vienna LS, Ducrocq V (2013) The Survival Kit : Software to
- analyze survival data including possibly correlated random effects.
- 373 https://doi.org/10.1016/j.cmpb.2013.01.010
- 18. Aghan E, Aziz O, Mbithe H, Surani S, Orwa J, Somji S (2021) Factors Associated
- 375 with Mortality Among Hospitalized Adults with COVID-19 Pneumonia at a Private
- 376 Tertiary Hospital in Tanzania : A Retrospective Cohort Study. 5431–5440

377	19.	Mammen JJ, Kumar S, Thomas L, et al (2021) Factors associated with mortality
378		among moderate and severe patients with 19 in India : a secondary analysis of a
379		randomised controlled trial. 1-10
380	20.	Mnyambwa NP, Lubinza C, Ngadaya E, et al (2022) Clinical characteristics and
381		outcomes of confirmed COVID-19 patients in the early months of the pandemic in
382		Tanzania : a multicenter cohort study. IJID Reg 2:118-125
383	21.	Agarwal N, Biswas B, Singh C, Nair R, Mounica G, Haripriya H, Jha AR, Das KM
384		(2021) Early Determinants of Length of Hospital Stay : A Case Control Survival
385		Analysis among COVID-19 Patients admitted in a Tertiary Healthcare Facility of East
386		India. https://doi.org/10.1177/21501327211054281
387	22.	Weya A, Id K, Id GA, Hurissa Z, Kaso T, Ewune HA, Hareru HE, Id AH (2022)
388		Survival analysis of COVID-19 patients in Ethiopia : A hospital-based study. 1-11
389	23.	Lackcy M c. B and elisabeth m. (2020) Categorization of COVID-19 severity to
390		determine mortality risk. FDA 19
391	24.	Ayana galana mamo (2021) Predictors of Mortality Among Hospitalized COVID-19
392		Patients at a Tertiary Care Hospital in. Infect drug Resist 5363-5373
393	25.	Pereira MLD (2020) Mortality and survival of COVID-19. Epidemilogy Infect 148:1-
394		6
395	26.	Ciceri F, Castagna A, Rovere-querini P, et al (2020) Early predictors of clinical
396		outcomes of COVID-19 outbreak in Milan , Italy. Clin Immunol 217:108509
397	27.	Bwire GM (2020) Coronavirus : Why Men are More Vulnerable to Covid-19 Than
398		Women? 874–876
399	28.	Wahaibi (2020) COVID-19 disease severity and mortality determinants: A large

population-based analysis in Oman. Travel Med. Infect. Dis. 39 101923 Contents

402 S1 Table: Proportions of COVID-19 patients who died by their background

403 characteristics (N=547)

VARIABLE(S)	TOTAL n(%)	DEAT	ГН	P-value
		Yes n (%)	No. n (%)	
Age categories in years				
Median (IQR)	63 (50-75)			
<60	223 (40.8)	48 (21.5)	175(78.5)	
60+	324 (59.2)	141 (43.5)	183(56.5)	<0.001
Sex				
Females	237 (43.3)	76 (32.1)	161 (67.9)	
Males	310 (56.7)	113(36.5)	197(63.5)	0.285
Reporting Region				
Arusha	48(8.8)	14 (29.2)	34 (70.8)	
Kilimanjaro	491(89.8)	172 (35.0)	319 (64.9)	
Others	8 (1.5)	3 (37.5)	5(62.5)	0.742

415 S2 Table: Proportions of COVID-19 patients who died by clinical features at admission

416 (N=547)

Variables	N (%)	I	P-value	
		Yes(%)	No(%)	
Median (IQR) Oxygen saturation at admission in %	70(53-82)			<0.001
Median Survival time (IQR) in	7(3-12)			0.0004
days	()			
Disease severity				
Mild	129 (23.6)	17 (13.2)	112 (86.8)	
Moderate	175 (31.9)	32 (18.3)	143 (81.7)	
Severe	243 (44.4)	140 (57.6)	103 (42.4)	<0.001
Clinical features				
Fever chills				
No	214 (39.1)	71 (33.2)	143(66.8)	
Yes	333 (60.8)	118 (35.4)	215 (64.6)	0.588
Headache				
No	455 (83.2)	159 (34.9)	296 (65.1)	
Yes	92 (16.8)	30 (32.6)	62 (67.4)	0.667
Nausea/Vomiting		, , ,	, , ,	
No	484 (88.5)	170 (35.1)	314 (64.9)	
Yes	63 (11.5)	19 (30.2)	44 (69.8)	0.436
Cough				
No	123 (22.5)	37 (30.1)	86 (69.9)	
Yes	424 (77.5)	152 (35.9)	272 (64.1)	0.236
Difficulty in breathing				
No	146 (26.7)	35 (23.9)	111(76.0)	
Yes	401 (73.3)	154 (38.4)	247 (61.6)	0.002
Chest pain				
No	295 (53.9)	96 (32.5)	199 (67.5)	
Yes	252 (46.1)	93 (36.9)	159 (63.1)	0.285
GBW				
No	157 (28.7)	49 (31.2)	108 (68.8)	
Yes	390 (71.3)	140 (35.9)	250 (64.1)	0.297
Sore throat				
No	507 (92.7)	179 (35.3)	328 (64.7)	
Yes	40 (7.3)	10 (25.0)	30 (75.0)	0.187
Runny nose				
No	519 (94.9)	183 (35.3)	336 (64.7)	
Yes	28 (5.1)	6 (21.4)	22 (78.6)	0.134
Smell loss				
No	502 (91.7)	178 (35.5)	324 (64.5)	
Yes	45 (8.2)	11 (24.4)	34 (75.6)	0.137
Loss of taste				
No	473 (86.5)	170 (35.9)	303 (64.1)	
Yes	74 (13.5)	19 (25.7)	55 (74.3)	0.084
Abdominal pain				
No	503 (91.9)	174 (34.6)	329 (65.4)	
Yes	44 (8.0)	15 (34.1)	29 (65.9)	0.947
Diarrhea				
No	503 (91.9)	179 (35.6)	324 (64.4)	0.00-
Yes	44 (8.0)	10 (22.7)	34 (77.3)	0.085
Waves	101 (10 -			
Wavel	101 (18.5)	25 (24.8)	76 (75.3)	
Wave2&3	375(68.6)	133 (35.5)	242 (64.5)	

Wave4 71 (12.9) 31 (43.7) 40 (56.3) 0.030					
	Wave4	71 (12.9)	31 (43.7)	40 (56.3)	0.030

418 S3 Table: Proportion of COVID-19 patients who died by comorbidities and radiological

findings (N=547)

Variables	n (%)	Died		P-value
		Yes(%)	No(%)	
Hypertension				
No	292 (53.4)	94 (32.2)	198 (67.8)	
Yes	255 (46.6)	95 (37.3)	160 (62.8)	0.214
Diabetes				
No	388 (70.9)	123 (31.7)	265 (68.3)	
Yes	159 (29.1)	66 (41.5)	93 (58.5)	0.028
Liver disease				
No	541 (98.9)	187 (34.6)	354 (65.4)	
Yes	6(1.1)	2 (33.3)	4 (66.7)	0.950
Asthma				
No	530 (96.9)	182 (34.3)	348 (65.7)	
Yes	17 (3.1)	7 (41.2)	10 (58.8)	0.560
Renal disease				
No	523 (95.6)	176 (33.7)	347 (66.4)	
Yes	24 (4.4)	13 (54.2)	11 (45.8)	0.039
Neurological disease				
No	534 (97.6)	182 (34.1)	352 (65.9)	
Yes	13 (2.4)	7 (53.9)	6 (46.1)	0.139
HIV				
No	535 (97.8)	185 (34.6)	350 (65.4)	
Yes	12 (2.2)	4 (33.3)	8 (66.7)	0.928
Malignancy				
No	521 (95.3)	178 (34.2)	343 (65.8)	
Yes	26 (4.7)	11 (42.3)	15 (57.7)	0.394
Radiological findings				
Abnormal chest				
No	89 (16.3)	17 (19.1)	72 (80.9)	
Yes	458 (83.7)	172 (37.6)	286 (64.5)	0.001
Abnormal lung				
No	273 (49.9)	79 (28.9)	194 (71.1)	
Yes	274 (50.1)	110 (40.2)	164 (59.8)	0.006

S4 Table: Sociodemographic predictors of mortality among COVID-19 patients

Variables	CHR (95%CI)	P-value
Age cat		
<60	1	
60+	2.62(1.88,3.66)	<0.001
Sex		
Females	1	
Males	1.35(1.00,1.83)	0.049
Reporting Region		
Arusha	1.00(0.29,3.53)	0.993
Kilimanjaro	1.08(0.35,3.39)	0.891
Others	1	

425			
426			
427			
428			
429			
430			
431			
432			
433			
434			
435			
436			
437			
438			
439			
440			

442 S5 Table: Clinical features predictors associated with mortality among COVID-19

443 patients

Variables	CHR (95%CI)	P-value
Disease severity		
Mild	1	
Moderate	1.91(1.03,3.53)	0.041
Severe	5.54(3.25,9.44)	<0.001
Fever chills (Yes)	1.27(0.94,1.72)	0.124
Headache (Yes)	1.02(0.68,1.54)	0.930
Nausea/Vomiting (Yes)	0.81(0.50,1.30)	0.380
Cough (Yes)	1.32(0.91,1.91)	0.144
Difficulty in breathing	1.56(1.06,2.28)	0.023
(Yes)		
Chest pain (Yes)	1.03(0.77,1.38)	0.833
GBW (Yes)	1.23(0.88,1.72)	0.223
Sore throat (Yes)	0.62 (0.32,1.21)	0.163
Runny nose (Yes)	0.81(0.36,1.83)	0.613
Smell loss (Yes)	0.93(0.50,1.70)	0.804
Loss of taste (Yes)	0.73(0.45,1.19)	0.206
Abdominal pain (Yes)	1.22(0.72,2.07)	0.466
Diarrhea (Yes)	0.72(0.38,1.36)	0.310
Waves		
Wave1	1	
Wave2&3	1.29(0.86,1.93)	0.220
Wave4	1.38(0.79,2.37)	0.257

455 S6 Table: Association between comorbidities, radiological findings and COVID-19

456 mortality

VARIABLE(S)	CHR (95%CI)	P-value
Hypertension		
Yes	1.27(0.95,1.71)	0.109
Diabetes		
Yes	1.33(0.98,1.82)	0.066
Liver disease		
Yes	1.00(0.25,4.05)	0.995
Asthma		
Yes	0.83(0.39,1.79)	0.652
Renal disease		
Yes	1.89(1.08,3.33)	0.027
Neurological disease		
Yes	1.87(0.87,3.97)	0.106
Immunodeficiency		
Yes	0.54(0.20,1.47)	0.228
Malignancy		
Yes	1.18(0.64,2.17)	0.596
Radiological findings		
Abnormal chest x-		
ray		
Yes	1.75(1.06,2.88)	0.028
Abnormal lung		
auscultation		
Yes	1.41(1.05,1.89)	0.024

VARIABLE (S)	CHR(95%CI)	P-value	AHR(95%CI)	P-value
Age cat				
60+	2.62 (1.88,3.66)	<0.001	2.01 (1.41,2.87)	<0.001
Sex				
Male	1.35 (1.00,1.83)	0.049	1.27 (0.93,1.73)	0.128
Clinical features				
Disease severity				
Mild	1		1	
Moderate	1.91 (1.03,3.53)	0.041	1.67 (0.89,3.13)	0.112
Severe	5.54 (3.35,9.44)	<0.001	4.44 (2.56,7.73)	<0.001
Difficultyinbreathing				
Yes	1.56 (1.06,2.28)	0.023	1.02 (0.68,1.52)	0.940
Waves				
Wave1	1		1	
Wave2&3	1.29 (0.86,1.93)	0.220	1.58 (1.03,2.41)	0.036
Wave4	1.38 (0.79,2.37)	0.257	1.07 (0.60,1.91)	0.811
Comorbidities				
Diabetes				
Yes	1.33 (0.98,1.82)	0.066	1.25 (0.88,1.79)	0.212
Hypertension				
Yes	1.27 (0.95,1.71)	0.109	0.94 (0.66,1.32)	0.713
Renal diseases				
Yes	1.89 (1.08,3.33)	0.027	1.26 (0.69,2.29)	0.438
Radiological findings				
Abnormal lung				
auscultation				
Yes	1.41 (1.05,1.89)	0.024	1.12 (0.82,1.53)	0.472
Abnormal chest x-				
ray				
Yes	1.75 (1.06,2.88)	0.028	1.38 (0.81,2.36)	0.235

465 S7 Table: Predictors of mortality among COVID-19 patients

466 **Note:** Bolded P-values indicates statistical significance variables

⁴⁶⁷ Key: CHR Hazard Ratio, AHR Adjusted Hazard Ratio, CI Confidence interval



Figure 1: (A)Kaplan-Meier survival plot showing overall survival; and Nelson-Aalen cumulative hazard plots showing mortality experience of COVID-19 patients at KCMC Hospital from 20th March 2020 to 26th Feb 2022 by (B)Age; (C)Disease severity; (D)Diabetes; (E)Sex; (F)Hypertension; (G)Lung auscultations; (H)Chest-x-ray; (I)Difficult in breathing; (J)Renal disease.

Figure



Figure 1: (A)Kaplan-Meier survival plot showing overall survival; and Nelson-Aalen cumulative hazard plots showing mortality experience of COVID-19 patients at KCMC Hospital from 20th March 2020 to 26th Feb 2022 by (B)Age; (C)Disease severity; (D)Diabetes; (E)Sex; (F)Hypertension; (G)Lung auscultations; (H)Chest-x-ray; (I)Difficult in breathing; (J)Renal disease.

Figure